Everest Medicines
-
Everest Medicines signs US$1.14B licensing agreement for Civorebrutinib with Travere
Under the agreement, Everest Medicines will receive US$112.5 million upfront from Travere Therapeutics and could earn up to US$1.03 billion more in milestone payments if certain clinical, regulatory, and commercial goals are met across five indications.
-
Everest Medicines shareholder CBC Group expands holdings amid strategic expansion
Since December 2025, CBC Group, together with the company’s directors have cumulatively purchased more than 3.062 million shares in the open market, amounting to over HK$113.8 million (US$14.56 million).
-
Everest Medicines expands Asia-Pacific footprint with US$250M Hasten Biopharmaceuticals acquisition
EverSea Medicines will make an initial payment of US$150 million at closing, followed by two additional payments of US$50 million each, scheduled for the first quarters of 2028 and 2029, subject to agreed conditions.
-
Everest Medicines announces ambitious 2030 growth strategy as leadership raises stakes
Everest Medicines plans to deliver predictable near-term value through commercializing existing assets, forming business development partnerships, and achieving in-house research and development milestones.
-
Everest Medicines expands its cardiovascular portfolio through strategic collaboration with Hasten Biopharmaceuticals
The collaboration is designed to strengthen Everest’s commercial operations in China while expanding its presence in the cardiovascular disease market.